Bernd Schlereth
- Oncology top 2%
- CAR-T cell therapy research 11
- Peptidase Inhibition and Analysis 3
- HER2/EGFR in Cancer Research 3
-
- Monoclonal and Polyclonal Antibodies Research 21
- Radiopharmaceutical Chemistry and Applications 3
- Immunology top 5%
- Immunotherapy and Immune Responses 4
- Toxin Mechanisms and Immunotoxins 4
- Biotechnology top 10%
-
- Glycosylation and Glycoproteins Research 4
- Co-authors
- Patrick A. BaeuerlePeter KuferKlaus BrischweinRobert HofmeisterGrit LorenczewskiRalf LutterbueseIduna FichtnerRalf Lutterbüse
- Journals
- Cancer Research (8 papers)Cancer Immunology Immunotherapy (4 papers)Journal of Immunotherapy (3 papers)
- Partner nations
- GermanySwedenSwitzerland
In The Last Decade
Bernd Schlereth
22 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 58
- Oncology 994
- Radiology, Nuclear Medicine and Imaging 832
- Immunology 622
- Biotechnology 62
- Molecular Biology 432
Countries citing papers authored by Bernd Schlereth
This map shows the geographic impact of Bernd Schlereth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Schlereth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Schlereth more than expected).
Fields of papers citing papers by Bernd Schlereth
This network shows the impact of papers produced by Bernd Schlereth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Schlereth. The network helps show where Bernd Schlereth may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bernd Schlereth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2022 | 1 | |
| 4 | 2022 | 1 | |
| 5 | 2009 | 144 | |
| 6 | 2009 | 43 | |
| 7 | 2009 | 64 | |
| 8 | 2008 | 30 | |
| 9 | 2008 | 16 | |
| 10 | 2008 | 68 | |
| 11 | 2007 | 66 | |
| 12 | Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3 | 2007 | 3 |
| 13 | 2007 | 146 | |
| 14 | 2006 | 10 | |
| 15 | 2005 | 77 | |
| 16 | 2005 | 212 | |
| 17 | 2005 | 206 | |
| 18 | 2005 | 101 | |
| 19 | 2005 | 44 | |
| 20 | 2003 | 155 |
About Bernd Schlereth
Bernd Schlereth is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, Immunology and Allergy and Inorganic Chemistry, having authored 23 papers that have together received 1.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (21 papers), CAR-T cell therapy research (11 papers), Glycosylation and Glycoproteins Research (4 papers), Immunotherapy and Immune Responses (4 papers), Toxin Mechanisms and Immunotoxins (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers), Peptidase Inhibition and Analysis (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Oncology (994 citations), Radiology, Nuclear Medicine and Imaging (832 citations), Immunology (622 citations), Biotechnology (62 citations) and Molecular Biology (432 citations). Bernd Schlereth has collaborated with scholars based in Germany, Sweden and Switzerland. Frequent co-authors include Patrick A. Baeuerle, Peter Kufer, Klaus Brischwein, Robert Hofmeister, Grit Lorenczewski, Ralf Lutterbuese, Iduna Fichtner, Ralf Lutterbüse, Mathias Locher and Petra Kleindienst. Their work appears in journals such as Cancer Research, Cancer Immunology Immunotherapy, Journal of Immunotherapy, Molecular Cancer Therapeutics and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.